894797-00-3

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
5-Chloropyrimidine-2-carboxylic acid methyl ester is used as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its versatile reactivity allows for the development of new compounds with potential therapeutic and pesticidal properties.
Used in Agriculture:
In the agricultural industry, 5-chloropyrimidine-2-carboxylic acid methyl ester is used as an intermediate in the production of dithiocarbamate fungicides. These fungicides are commonly used to control fungal diseases in crops, thereby protecting agricultural yields.
Used in Medicinal Chemistry Research:
5-Chloropyrimidine-2-carboxylic acid methyl ester has been studied for its potential antiviral and antitumor properties. Its biological activities make it a valuable compound for research in the field of medicinal chemistry, with the potential to contribute to the development of new treatments for viral infections and cancer.

Upstream product

• 67-56-1 methanol 
• 38275-56-8 5-chloropyrimidine-2-carbonitrile 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol "APLNR"). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.